Format

Send to:

Choose Destination
See comment in PubMed Commons below
Allergy Asthma Proc. 2012 Mar-Apr;33(2):129-39. doi: 10.2500/aap.2012.33.3525.

Allergic conjunctivitis: the evolution of therapeutic options.

Author information

  • 1Rutgers University, Center for Environmental Prediction, Robert Wood Johnson University Hospital, Springfield, New Jersey, USA. bielory@envsci.Rutgers.edu

Abstract

The eye has become the target of intense pharmacologic development because it represents one of the most active sites of allergic inflammation, due to it having no mechanical barrier to prevent the impact of allergens such as pollen on its surface. Over the past 20 years, we have witnessed an astonishing growth in therapeutic advances, ranging essentially from derivatives of simple aspirin to various newly developed biological immunomodulatory agents, using implantable drug delivery devices that exceed the safety and efficacy of those available for other organ systems and resorting to advanced surgical techniques for the correction of sight-threatening, disease-related complications. Overall, with the expanding knowledge base, the intricacy of ocular inflammation appears to be becoming ever more manageable and the clinical allergist/immunologist has an increasing role in the treatment outcomes of patients with anterior inflammatory disorders of the ocular surface primarily allergic conjunctivitis but also including dry eye syndromes.

PMID:
22525389
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Ingenta plc
    Loading ...
    Write to the Help Desk